{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T07:58:11Z","timestamp":1772265491680,"version":"3.50.1"},"reference-count":19,"publisher":"American Society of Tropical Medicine and Hygiene","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,1,8]]},"abstract":"<jats:p>Fear of adverse events (AEs) negatively affects compliance to mass drug administration (MDA) for lymphatic filariasis (LF) elimination program. Systemic AEs are believed to occur because of killing of microfilariae, whereas localized soft tissue reactions might be due to the death of adult worms following therapy. Most AEs are mild and self-limited. However, localized AEs are sometimes more significant and of concern to participants. Here, we describe localized AEs that were noted during a large community study that evaluated the safety of a triple-drug regimen (ivermectin, diethylcarbamazine, and albendazole) for the treatment of LF in India. We have also discussed the importance of timely detection and careful management of AEs for preserving community confidence in MDA.<\/jats:p>","DOI":"10.4269\/ajtmh.19-0532","type":"journal-article","created":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T07:00:52Z","timestamp":1574751652000},"page":"96-99","source":"Crossref","is-referenced-by-count":9,"title":["Frequency and Clinical Significance of Localized Adverse Events following Mass Drug Administration for Lymphatic Filariasis in an Endemic Area in South India"],"prefix":"10.4269","volume":"102","author":[{"given":"Vijesh Sreedhar","family":"Kuttiatt","sequence":"first","affiliation":[{"name":"ICMR-Vector Control Research Centre, Puducherry, India;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roopali K.","family":"Somani","sequence":"additional","affiliation":[{"name":"ICMR-Vector Control Research Centre, Puducherry, India;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Subramanian","family":"Swaminathan","sequence":"additional","affiliation":[{"name":"ICMR-Vector Control Research Centre, Puducherry, India;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaliannagounder","family":"Krishnamoorthy","sequence":"additional","affiliation":[{"name":"ICMR-Vector Control Research Centre, Puducherry, India;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary J.","family":"Weil","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jambulingam","family":"Purushothaman","sequence":"additional","affiliation":[{"name":"ICMR-Vector Control Research Centre, Puducherry, India;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2795","reference":[{"key":"b1","series-title":"Wkly Epidemiol Rec","first-page":"589","article-title":"Global programme to eliminate lymphatic filariasis: progress report 2017","volume":"44","author":"WHO","year":"2018"},{"key":"b2","series-title":"PLoS Negl Trop Dis","first-page":"e2447","article-title":"A review of factors that influence individual compliance with mass drug administration for elimination of lymphatic filariasis","volume":"7","author":"Krentel","year":"2013"},{"key":"b3","series-title":"Clin Infect Dis","first-page":"334","article-title":"Efficacy, safety, and pharmacokinetics of coadministered diethylcarbamazine, albendazole, and ivermectin for treatment of bancroftian filariasis","volume":"62","author":"Thomsen","year":"2016"},{"key":"b4","series-title":"N Engl J Med","first-page":"1801","article-title":"A trial of a triple-drug treatment for lymphatic filariasis","volume":"379","author":"King","year":"2018"},{"key":"b5","article-title":"Triple drug study for filariasis elimination. A community based study to compare the safety, efficacy and acceptability of a triple drug regimen (ivermectin, diethylcarbamazine and albendazole) with a two drug regimen (diethylcarbamazine and albendazole) for lymphatic filaraisis elimination program"},{"key":"b6","series-title":"PLoS Med","first-page":"e1002839","article-title":"The safety of double- and triple-drug community mass drug administration for lymphatic filariasis: a multicenter, open-label, cluster-randomized study","volume":"16","author":"Weil","year":"2019"},{"key":"b7","series-title":"PLoS Negl Trop Dis","first-page":"e0006454","article-title":"Adverse events following single dose treatment of lymphatic filariasis: observations from a review of the literature","volume":"12","author":"Budge","year":"2018"},{"key":"b8","series-title":"Wkly Epidemiol Rec","first-page":"315","article-title":"Report on active surveillance for adverse events following the use of drug co-administrations in the global program to eliminate lymphatic filariasis","volume":"36","author":"WHO","year":"2003"},{"key":"b9","series-title":"Trans R Soc Trop Med Hyg","first-page":"464","article-title":"Adverse reactions following mass drug administration during the Programme to Eliminate Lymphatic Filariasis in Orissa State, India","volume":"100","author":"Babu","year":"2006"},{"key":"b10","series-title":"Rev Soc Bras Med","first-page":"745","article-title":"Adverse reactions following mass drug administration with diethylcarbamazine in lymphatic filariasis endemic areas in the Northeast of Brazil","volume":"45","author":"Lima","year":"2012"},{"key":"b11","series-title":"Am J Trop Med Hyg","first-page":"568","article-title":"Frequency, severity, and costs of adverse reactions following mass treatment for lymphatic filariasis using diethylcarbamazine and albendazole in Leogane, Haiti, 2000","volume":"68","author":"McLaughlin","year":"2003"},{"key":"b12","series-title":"Rev Infect Dis","first-page":"341","article-title":"Efficacy of diethylcarbamazine in eradicating infection with lymphatic-dwelling filariae in humans","volume":"7","author":"Ottesen","year":"1985"},{"key":"b13","series-title":"Ann Trop Med Parasitol","first-page":"235","article-title":"Antifilarial drugs, in the doses employed in mass drug administrations by the global programme to eliminate lymphatic filariasis, reverse lymphatic pathology in children with Brugia malayi infection","volume":"103","author":"Shenoy","year":"2009"},{"key":"b14","series-title":"PLoS Negl Trop Dis","first-page":"e0005631","article-title":"Lymphatic pathology in asymptomatic and symptomatic children with Wuchereria bancrofti infection in children from Odisha, India and its reversal with DEC and albendazole treatment","volume":"11","author":"Kar","year":"2017"},{"key":"b15","series-title":"Am J Trop Med Hyg","first-page":"471","article-title":"Duplex doppler sonographic assessment of the effects of diethylcarbamazine and albendazole therapy on adult filarial worms and adjacent host tissues in bancroftian filariasis","volume":"71","author":"Hussein","year":"2004"},{"key":"b16","series-title":"Trop Biomed","first-page":"19","article-title":"Treatment of bancroftian filariasis with albendazole: evaluation of efficacy and adverse reactions","volume":"10","author":"Jayakody","year":"1993"},{"key":"b17","series-title":"Ann Trop Med Parasitol","first-page":"579","article-title":"Treatment of microfilaraemia in asymptomatic brugian filaraisis: the efficacy and safety of the combination of single doses of ivermectin and diethylcarbamazine","volume":"92","author":"Shenoy","year":"1998"},{"key":"b18","series-title":"Assuring Safety of Preventive Chemotherapy Interventions for the Control of Neglected Tropical Diseases: Practical Advice for National Programme Managers on the Prevention, Detection and Management of Serious Adverse Events","author":"WHO","year":"2011"},{"key":"b19","article-title":"Guidelines for assuring safety of preventive chemotherapy"}],"container-title":["The American Journal of Tropical Medicine and Hygiene"],"original-title":[],"link":[{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/102\/1\/article-p96.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/102\/1\/article-p96.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/102\/1\/article-p96.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T21:56:44Z","timestamp":1722463004000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/102\/1\/article-p96.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,8]]},"references-count":19,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.4269\/ajtmh.19-0532","relation":{},"ISSN":["0002-9637","1476-1645"],"issn-type":[{"value":"0002-9637","type":"print"},{"value":"1476-1645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,8]]}}}